Deals channel feed

Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

Last year
China

As­traZeneca inks $247M deal with gen­er­a­tive AI shop Ab­sci to de­vel­op an­ti­body drug for can­cer

Last year
AI

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Last year

Af­ter tar­get­ing strug­gling biotechs, Tang’s Con­cen­tra shifts gears with un­so­licit­ed bid for Lian­Bio

Last year

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

Last year
Pharma

Up­dat­ed: Ab­b­Vie to ac­quire Im­muno­Gen for $10B in ban­ner year for AD­Cs

Last year
Pharma

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Last year
AI

Il­lu­mi­na CFO says there's out­side in­ter­est in Grail as 'outright sale' ex­plored

Last year

Bris­tol My­ers bets $100M on Avid­i­ty's RNA ther­a­pies for car­dio­vas­cu­lar dis­eases

Last year
R&D
Pharma

So­sei Hep­tares to take back GPCR ag­o­nist af­ter GSK changes course

Last year

Tang’s Con­cen­tra faces off with Fore­site, Or­biMed in buy­out bat­tle for strug­gling biotech The­seus

Last year

Boehringer ac­quires Uni­ver­si­ty of Basel spin­out for $507M to de­vel­op im­munother­a­pies

Last year
Pharma

Nvidia signs deal with Genen­tech to pair drug­mak­er's ma­chine learn­ing with chip sup­pli­er's tech

Last year
AI

Up­dat­ed: Mer­ck com­mits up to $610M to buy out pre­clin­i­cal biotech and its neu­rode­gen­er­a­tive dis­ease work

Last year

BeiGene li­cens­es CDK2 in­hibitor from En­sem in po­ten­tial $1.33B deal

Last year

Am­gen lines up new AI biotech part­ner in PostEra to de­vel­op small mol­e­cule med­i­cines

Last year
AI

Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

Last year
Startups

Astel­las bags prostate can­cer drug in $175M buy­out as Xtan­di ap­proach­es patent cliff

Last year

In­vestors Or­biMed and Fore­site say they're look­ing at tak­ing Kin­nate pri­vate, fol­low­ing pipeline and staff cuts

Last year

Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Last year

Gilead­'s Kite dou­bles down on Ar­cel­lx's blood can­cer cell ther­a­pies with $285M

Last year
Cell/Gene Tx

Leg­end signs $100M deal with No­var­tis for next CAR-T bets, fol­low­ing up on Janssen suc­cess

Last year
Cell/Gene Tx

Aji­nomo­to to buy gene ther­a­py CD­MO Forge Bi­o­log­ics in $620M all-cash deal

Last year
Manufacturing

Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Last year
R&D
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times